Efficacy and safety of fumaric acid esters in the long-term treatment of psoriasis - A retrospective study (FUTURE);Wirksamkeit und Sicherheit von Fumarsäureestern in der Langzeittherapie der Psoriasis - Eine Retrospektive Studie (FUTURE)

JDDG - Journal of the German Society of Dermatology

Volumn 7, Issue 7, 2009, Pages 603-610

  Reich, Kristian ^a,e   Thaci, Diamant ^b   Mrowietz, Ulrich ^c   Kamps, Anja ^d   Neureither, Marcus ^d   Luger, Thomas ^d  

^a Dermatologikum Hamburg   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e NONE   (Germany)

Author keywords

Fumaric acid esters; Long term study; Psoriasis

Indexed keywords

ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUMADERM; METHOTREXATE; RETINOID;

ADULT; ARTICLE; BLOOD CELL COUNT; CLINICAL ASSESSMENT; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EOSINOPHILIA; FEMALE; FLUSHING; HUMAN; KIDNEY FUNCTION; LABORATORY TEST; LEUKOPENIA; LIVER FUNCTION; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; PHOTOTHERAPY; PSORIASIS; RECOMMENDED DRUG DOSE; SIDE EFFECT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 68149087714     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2009.07120.x     Document Type: Article

References (22)

1. Augustin M, Küger K, Radtke M A, Schwippel I, Reich K. Disease severity, quality of life and health care in plaquetype psoriasis: a multicenter cross-sectional study in Germany. Dermatology 2008 216 : 366 72.
2. Nast A, Kopp IB, Augustin M, Banditt KB, Boehncke WH, Follmann M, Friedrich M, Huber M, Kahl C, Klaus J, Koza J, Kreiselmaier I, Mohr J, Mrowietz U, Ockenfels HM, Orzechowski HD, Prinz J, Reich K, Rosenbach T, Rosumeck S, Schlaeger M, Schmid-Ott G, Sebastian M, Streit V, Weberschock T, Rzany B Deutsche Dermatologische Gesellschaft. S3-Leitlinie zur Therapie der Psoriasis vulgaris. J Dtsch Dermatol Ges 2006 4 (Suppl 2 S1 126.
3. Augustin M, Reich K, Reich Ch, Purwins S, Rustenbach St J, Schäfer I, Radtke M. Versorgungsqualität der Psoriasis vulgaris in Deutschland - Er-gebnisse der Nationalen Versorgungs-studie PsoHealth 2007. J Dtsch Dermatol Ges 2008 8 : 640 6.
4. Mrowietz U, Elder JT, Barker J. The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients. Arch Dermatol Res 2006 298 : 309 19.
5. Boehncke S, Thaci D, Beschmann H, Ludwig RJ, Ackermann H, Badenhoop K, Boehncke WH. Psoriasis patients show signs of insulin resistance. Br J Dermatol 2007 157 : 1249 51.
6. Wu Y, Mills D, Bala M. Psoriasis: cardiovascular risk factors and other disease comorbidities. J Drugs Dermat 2008 4 : 373 7.
7. Gelfand JM, Troxel AB, Lewis JD, Kurd SK, Shin DB, Wang X, Margolis DJ, Strom BL. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007 143 : 1493 9.
8. Jacobsson LT, Turesson C, Gulfe A, Kapetanovic MC, Petersson IF, Saxne T, Geborek P. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005 32 : 1213 8.
9. Dixon WG, Symmons DPM. What effects might anti-TNFα treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFα in cardiovascular pathophysiology. Ann Rheum Dis 2007 66 : 1132 6.
10. Reich K, Mrowietz U. Therapieziele bei der Behandlung der Psoriasis. J Dtsch Dermatol Ges 2007 5 : 566 75.
11. Mrowietz U, Asadullah K. Dimethylfumarate for psoriasis: more than a dietary curiosity. Trends Mol Med. 2005 11 : 43 8.
12. Litjens NH, Nibbering PH, Barrois AJ Zomerdijk TP, Van Den Oudenrijn AC, Noz KC, Rademaker M, Van De Meide PH, Van Dissel JT, Thio B. Beneficial effects of fumarate therapy in psoriasis vulgaris patients coincide with downregulation of type 1 cytokines. Br J Dermatol 2003 148 : 444 51.
13. Ormerod AD, Mrowietz U. Fumaric acid esters, their place in the treatment of psoriasis. Br J Dermatol 2004 150 : 630 2.
14. Bayard W, Hunziker T, Krebs A, Speiser P, Joshi R. Perorale Langzeitbehandlung der Psoriasis mit Fumarsäurederi-vaten. Hautarzt 1987 38 : 279 85.
15. Nugteren-Huying WM, Van Der Schroeff JG, Hermans J, Suurmond D. Fumaric acid therapy in psoriasis: a double-blind, placebo-controlled study. Ned Tijdschr Geneeskd 1990 134 : 2387 91.
16. Kolbach DN, Nieboer C. Fumaric acid therapy in psoriasis: results and side effects of 2 years of treatment. J Am Acad Dermatol 1992 27 : 769 71.
17. Altmeyer PJ, Mathhes U, Pawlak F, Hoffmann K, Frosch P, Ruppert P, Sawko WW, Horn T, Kreysel HW, Lutz G, Barth J, Rietzschel I, Rajendra K, Joshi K. Antipsoriatic effect of fumaric acid derivatives. Results of a multicentre double-blind study in 100 patients. J Am Acad Dermatol 1994 30 : 977 81.
18. Altmeyer PJ, Hartwig P, Mathhes U. Das Wirkungs- und Sicherheitsprofil von Fumarsäureestern in der oralen Langzeittherapie bei schwerer therapie-resistenter Psoriasis vulgaris. Eine Untersuchung an 83 Patienten. Hautarzt 1996 47 : 190 6.
19. Mrowietz U, Christophers E, Altmeyer P. Treatment of psoriasis with fumaric acid esters: results of a prospective mul-ticentre study. Br J Dermatol 1998 138 : 456 60.
20. Gollnick H, Altmeyer P, Kaufmann R, Ring J, Christophers E, Pavel S, Ziegler J. Topical calcipotriol plus oral fumaric acid is more effective and faster acting than oral fumaric acid monotherapy in the treatment of severe chronic plaque psoriasis vulgaris. Dermatology 2002 205 : 46 53. (Pubitemid 36152961)
21. Carboni I, De Felice C, De Simoni, Soda R, Chimenti S. Fumaric acid esters in the treatment of psoriasis: an Italian experience. J Dermatolog Treat 2004 15 : 23 6.
22. Gerdes S, Zahl VA, Knopf H, Weichenthal M, Mrowietz U. Comedication related to comorbidities: a study in 1203 hospitalized patients with severe psoriasis. Br J Dermatol 2008 159 : 1116 23.